New capabilities transform rigid company and team operations, complex payment setups, and developer workflows into seamless, natural-language actions—drastically shortening the bridge between product launch and revenue.

SAN FRANCISCO, June 13, 2026 /PRNewswire/ — Subotiz, the AI-driven subscription commerce and payment infrastructure platform tailored for AI, SaaS, and digital entertainment enterprises, recently announced the launch of its pioneering AI Agent Suite and Subotiz MCP Server. This unified release introduces a powerful new layer of capability, enabling AI companies and developers to architect, manage, and scale global subscription commerce entirely through natural language.

The launch addresses a critical bottleneck in the fast-moving digital economy. While the generative AI boom has made building a digital product faster and cheaper than ever, the commercialization phase remains bogged down by legacy complexity. Transitioning from a viable product to a revenue-generating business still requires navigating fractured workflows: configuring complex subscription tiers, aligning localized payment gateways, auditing data anomalies, and debugging developer APIs.

Traditionally, these tasks forced lean teams to context-switch across disconnected dashboards, dense API references, and internal support tickets. Subotiz is collapsing these silos into a single, cohesive, AI-assisted operating experience. While the AI Agent Suite automates complex operational workflows inside the Subotiz platform, the Subotiz MCP Server allows external AI tools to hook directly into Subotiz’s subscription, billing, and developer pipelines.

“AI shouldn’t just answer user prompts; it should execute heavy-lifting operational workflows,” said Ryan Yang, Solution Director at Subotiz. “With our AI Agent Suite and MCP Server, we are shifting subscription commerce from manual configuration to intent-driven execution. Companies simply describe the business outcome they want, and Subotiz translates that intent into production-ready operational and technical reality.”

The AI Agent Suite: Five Specialized Agents, One Conversational Dashboard

Rather than relying on a generic chatbot, Subotiz has engineered five purpose-built agents mapped to high-frequency subscription commerce friction points:

• The Collect Agent (Frictionless Intake): Streamlines the initial onboarding grind. By ingestion of unstructured business context during registration, it eliminates the need to study compliance documentation, automatically recommending tailored payment methods, optimal pricing structures, and localized operational setups.

• The Onboard Agent (Accelerated Time-to-Value): Cross-references merchant profiles with Subotiz’s proprietary business strategy library to map out a customized, step-by-step launch path, auto-filling technical configuration fields to accelerate time-to-market.

• The Merchant Agent (Conversational Operations): Acts as a 24/7 co-pilot for daily business tweaks. Through multi-turn natural language conversations that retain context, users can spin up new subscription products, modify pricing plans, or update business settings without digging through menus.

• The Data Agent (Proactive Business Diagnosis): Moves beyond passive, static reporting. The agent actively detects revenue anomalies, analyzes root causes behind churn or transaction drops, drills into subscription patterns, and delivers visual, actionable optimization strategies.

• The Email Agent (Natural-Language HTML Editing): Empowers marketing and ops teams to modify transactional HTML email templates dynamically. Users can command font changes, adjust CTA placements, or insert compliance language via natural text. The agent features real-time visual previews, version controls, and automated risk checks for sensitive words and broken links.

Extending AI to the Dev Environment via Model Context Protocol (MCP)

Recognizing that modern tech teams live inside their code editors, Subotiz is extending this natural-language capability directly into the developer workflow via the Subotiz MCP Server. Built on the open-source Model Context Protocol (MCP), the emerging standard for connecting AI assistants to secure data sources, Subotiz allows teams to manage their billing infrastructure straight from environments like Cursor, VS Code and Claude Desktop.

Through the Subotiz MCP Server, engineers and operations teams can query or create customer profiles, adjust pricing plans, audit live webhook event logs, inspect refund histories, and retrieve documentation using natural language commands. This eliminates the need to manually write boilerplate API scripts for routine troubleshooting and testing.

The real-world impact is already clear for lean, high-growth startups. In a recent deployment, a short-form digital content provider with zero dedicated back-end engineers utilized Subotiz’s embedded payment modules, automated compliance support, and MCP-driven testing environment to successfully simulate and validate its first subscription payment pipeline in just three days, all without writing a single line of custom code.

“Product iteration cycles have collapsed to days, but monetization remains trapped in weeks of configuration,” said Adam Mawdesley, Chief Revenue Officer of Subotiz. “Subotiz is closing that final gap. We are ensuring that business intent instantly translates into working payment and subscription infrastructure.”

The AI Agent Suite and Subotiz MCP Server are available now to all Subotiz users worldwide.

About Subotiz

Subotiz is a next-generation payment and revenue infrastructure platform designed for global digital businesses. By combining payments, subscription management, usage-based billing, tax and compliance automation, and fraud prevention into a unified platform, Subotiz enables SaaS, AI, eCommerce, and platform businesses to scale globally with greater operational efficiency and revenue flexibility. Learn more at Subotiz.

News Summary:

• Relativity has acquired Gavel, an AI-native legal technology company whose solutions are used by thousands of legal professionals to draft, review and automate legal work product.
• With the integration of Gavel, work product created in RelativityOne and Relativity aiR could be opened, drafted, edited, redlined and finalized inside Microsoft Word, with each edit syncing back to the matter in RelativityOne.
• The Gavel team joins Relativity, bringing deep expertise in AI-native drafting, document automation and the Microsoft Word experience that lawyers depend on.

CHICAGO, June 13, 2026  /PRNewswire/ — Relativity, a legal data intelligence company, today announced its acquisition of Gavel, an AI-native legal technology company whose solutions are used by thousands of legal professionals to draft, review and automate work product directly in Microsoft Word and on the web. Through the acquisition, Relativity plans to extend its AI platform for legal data intelligence into Microsoft Word, helping keep work product connected to the data and context behind matters.

“We believe that Relativity’s role as a driving force in legal AI innovation requires investing in the technology and people that create real value for our customers and partners. We’re delivering on that through Rel Labs, our partnership and startup investment program, and strategic moves like this one,” said Phil Saunders, CEO of Relativity. “This acquisition enhances our ability to support a wider arc of legal work, in the place where lawyers spend most of their time. The Gavel team is exceptional, and we’re excited to come together and bring what they’ve built to the Relativity community.”

RelativityOne serves as the AI platform for legal data intelligence and the system of action where teams organize, analyze and act on the evidence at the heart of their most important matters. Yet the documents that follow from that work—motions, briefs and contracts—have historically remained in Microsoft Word, separate from the data and context that shaped them. With Relativity’s integration of Gavel, that work should no longer need to leave the platform, deepening attorney engagement with RelativityOne across the full matter lifecycle.

Work product generated by Relativity aiR for Case Strategy, aiR Assist and more could become editable directly in Microsoft Word, enabling lawyers to refine, route for comments and redlines, and finalize documents within their natural workflow. Every change could sync back to the matter in RelativityOne, creating a more connected experience where legal intelligence and the work product it shapes move together.

“With Gavel, drafting and collaboration happen directly in Microsoft Word. Once integrated with RelativityOne, that work could happen against the full context of the matter, with edits syncing back to the platform,” said Chris Brown, Chief Product Officer at Relativity. “We would be taking the system of action that lawyers already rely on and extending it into the surfaces where they actually do the work.”

Gavel was founded by Dorna Moini, a former associate at Sidley Austin LLP, who began building document automation tools for pro bono clients and eventually grew Gavel into an AI-native platform used by legal teams worldwide. Gavel’s Chief Technology Officer, Pierre Martin, joined the company in 2022, bringing deep experience at the intersection of AI and enterprise software, with previous leadership and executive roles at Microsoft, Amazon and high-growth startups. Now, the Gavel team joins Relativity with a shared commitment to helping legal professionals work smarter, move faster and act with greater confidence.

“This is an exciting next chapter for Gavel employees and our customers,” said Dorna Moini, Founder and CEO of Gavel. “Joining Relativity gives us an unrivaled opportunity to scale our shared vision for the industry, build faster and bring our technology to more legal teams. Relativity’s footprint, data platform and deep trust across the legal industry will help us take everything we’ve built at Gavel to the next level.”

Law firms and organizations across 28 countries use Gavel to draft, edit and automate legal work product with a combination of generative AI and rules-based workflows. Operating in Microsoft Word and on the web, Gavel supports drafting, contract review, redlining and analysis with contextual guidance grounded in legal norms and playbooks, helping work product stay consistent with firm standards and connected to the most relevant information.

Relativity’s immediate focus is on thoughtful integration and continuity for customers. The company intends to maintain Gavel’s regular operations while bringing its capabilities into RelativityOne over time.

About Relativity 
Relativity is a leading legal data intelligence company that builds technology to help users organize data, discover the truth, and act on it. Its extensible, AI cloud platform, RelativityOne, transforms complex data into actionable insights at massive scale for litigation, investigations, regulatory inquiries, data breach responses, and other legal use cases. The world’s largest law firms and corporations, government agencies, and a robust network of channel partners rely on Relativity’s legal AI software to securely surface and manage the most relevant and impactful information in their matters. The company also expands access to technology by providing its platform at no cost to academic institutions through its Relativity Academic program and to organizations supporting pro bono legal work through its Justice for Change initiative. 

CONTACT: PR@relativity.com

LOS ANGELES, June 13, 2026 /PRNewswire/ — Insta360 has filed two countersuits against DJI in the U.S., asserting five utility patents covering technology used in gimbal and 360-degree cameras.

The company asserts that DJI infringed its patents relating to gimbal stabilization, gimbal directional control, camera smooth stabilization, telemetry overlay, and panoramic video stabilization. These technologies are incorporated into several major DJI products, including the Osmo Pocket series, Ronin/RS series, Osmo Mobile series, and Osmo 360.

“At Insta360, we prefer to let our products do the talking. But we are not afraid of a legal battle when challenged,” said JK Liu, Founder of Insta360. “We are fully committed to protecting our innovations and will take decisive action to defend our intellectual property from infringement.”

These countersuits are a direct response to patent lawsuits initiated by DJI on June 10—the day Insta360 launched its Luna Ultra camera. DJI’s legal action seeks a permanent injunction to ban Luna Ultra from the U.S. market. 

Insta360 categorically rejects DJI’s infringement claims regarding the new Luna Ultra camera, emphasizing the device’s unique engineering footprint.

“Luna Ultra is the result of years of independent R&D, not a response to any competitor’s product,” added Liu. “Development began in 2020, with earlier Insta360 products including the ONE R, Link Series webcams, and Flow Series gimbals helping shape the technology and design direction behind Luna Ultra. DJI filing lawsuits on the same day we launched Luna Ultra speaks volumes—exposing their fear of competition from a highly competitive product.”

Initial consumer response has been strong, with Luna Ultra seeing significant demand in North America and ranking as the top seller in Amazon’s camcorder category in the U.S. over its first 24 hours of availability. Insta360 remains fully committed to defending its IP portfolio while working to ensure the continued availability of its products for creators worldwide.

Insta360

With a “Think bold” mindset, Insta360 empowers people to capture and share their lives in extraordinary ways. Recognized as a market leader and innovator, Insta360’s vast lineup includes the world’s best-selling 360 cameras in the X Series, the pocket-sized GO Series for everyday capture, as well as an extensive range of action cameras, gimbals, webcams, and professional photography solutions. With intuitive, AI-powered software, Insta360 simplifies the creative process, allowing users to focus on storytelling without technical barriers. Insta360 is dedicated to helping a new generation of athletes, creatives, travelers and professionals bring their ideas to life.

For more details visit: http://www.insta360.com
About the Think Bold Fund: https://www.insta360.com/ThinkBoldFund
Read our blog: https://www.insta360.com/blog
Follow us on Facebook: https://www.facebook.com/Insta360
Follow us on X: https://x.com/insta360
Follow us on Instagram: http://www.instagram.com/insta360
Follow us on TikTok: http://tiktok.com/@insta360_official
Follow us on LinkedIn: https://www.linkedin.com/company/insta360
Subscribe to our YouTube Channel: http://www.youtube.com/insta360

Press Contact
Insta360
pr@insta360.com

• Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals.
• Findings were presented at the European Society of Cardiology’s ACNAP Congress 2026, organised by the Association of Cardiovascular Nursing & Allied Professions, the leading congress for nurses and allied professionals committed to advancing patient-centred cardiovascular care.

GALWAY, Ireland, June 13, 2026 /PRNewswire/ — Global Heart Hub, the international alliance of heart patient organisations, has released insights from their latest patient-led qualitative research study exploring women’s experiences with cardiovascular disease. The findings reveal that women are slow to seek medical help and there are ongoing gaps in the recognition and diagnosis of heart disease in women despite it remaining the leading cause of death among women globally.

The study, IPEC2 (Insights & Patient Experiences with Cardiovascular Disease), collected patient experience data from women across eight countries and includes women with elevated low-density lipoprotein cholesterol (LDL-C), elevated LP(a), heart valve disease and cardiomyopathy. The research explored women’s experiences of heart disease; their awareness and recognition of cardiovascular symptoms; barriers across the care pathway and assessed the burden of managing heart disease on women’s lives. The Global Heart Hub study is guided by both an independent Steering Committee and Review Committee. The committees are comprised of people with lived experience, patient organisation leaders and international clinical experts.

ACNAP 2026

IPEC2 preliminary findings were presented at the European Society of Cardiology’s ACNAP Congress 2026 on 12 June, focusing on women with elevated low-density lipoprotein cholesterol who were hospitalised at least once for a cardiac event (heart attack, stroke, or unstable angina). Uncontrolled elevated LDL cholesterol is a primary driver of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death in women across the world. The IPEC2 preliminary findings included women aged 18 years or older in the US, Canada, China and Italy.

“We now have incredible therapies to deal with high LDL-C ‘bad cholesterol’. However, the study findings highlight that women may not receive a timely diagnosis and, therefore, cannot access any treatment. The reasons are due to delays in women seeking care, frequently putting others (family) before their own health. In addition, the findings describe delays in diagnosis due to under-recognition of symptoms, life factors and clinician bias. This means that women continue to be treated later in the disease progression, sometimes at the point of their life-threatening cardiac event, which often diminishes their opportunity for better outcomes,” says Professor Vijay Kunadian, Professor of Interventional Cardiology and Cardiovascular Medicine, Newcastle University & Newcastle Hospitals, UK; and Member of IPEC2’s Steering Committee.

The preliminary findings reveal that women across every focus group experienced perceived bias in their healthcare journey, sharing their perceptions of times in their diagnosis and treatment journey where others indicated they were “too young” or “not the type” for cardiovascular disease. The gender bias in diagnosis is also evident, with women reporting that their cardiovascular disease symptoms were commonly misdiagnosed as other non-cardiac conditions, most frequently anxiety. Women described a broad and varied range of cardiovascular symptoms, including symptoms beyond those reported in guidelines. These findings highlight the need for improved symptom recognition and patient education to support earlier identification and more equitable, patient-centred care across cardiovascular settings.

“Cardiovascular disease is the leading cause of death among women, and the IPEC2 findings confirm that women continue to experience late, missed or misdiagnosed heart disease, often compounded by fragmented care. Women often experience symptoms that differ from those traditionally described in men, yet these are frequently not recognised as cardiac. We need to think ‘heart first’ for every woman, everywhere,” says Neil Johnson, Executive Director, Global Heart Hub.

IPEC2 seeks to deepen understanding of women’s experiences with cardiovascular disease by collecting robust patient experience data. The research guides recommendations towards improving patient care for women. The preliminary findings highlighted the need for improved symptom recognition and patient education to support earlier identification and more equitable, patient-centred care across cardiovascular settings.

Learn more about IPEC2: globalhearthub.org/ipec2 

Global Heart Hub’s Insights and Patient Experiences with Cardiovascular Disease (IPEC) study is a patient-led initiative made possible with the support of Amgen Inc., Daiichi Sankyo Europe, and Novartis Pharmaceuticals Corporation.

About Global Heart Hub:

Established in 2019 and headquartered in Ireland, Global Heart Hub (GHH) is the first international non-profit organisation established to provide a voice for those living with, or affected by, cardiovascular disease. We are an alliance of 150+ heart patient organisations across 40+ countries, aiming to create a unified global voice for those living with or affected by heart disease. Learn more: globalhearthub.org

• Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals.
• Findings were presented at the European Society of Cardiology’s ACNAP Congress 2026, organised by the Association of Cardiovascular Nursing & Allied Professions, the leading congress for nurses and allied professionals committed to advancing patient-centred cardiovascular care.

GALWAY, Ireland, June 13, 2026 /PRNewswire/ — Global Heart Hub, the international alliance of heart patient organisations, has released insights from their latest patient-led qualitative research study exploring women’s experiences with cardiovascular disease. The findings reveal that women are slow to seek medical help and there are ongoing gaps in the recognition and diagnosis of heart disease in women despite it remaining the leading cause of death among women globally.

The study, IPEC2 (Insights & Patient Experiences with Cardiovascular Disease), collected patient experience data from women across eight countries and includes women with elevated low-density lipoprotein cholesterol (LDL-C), elevated LP(a), heart valve disease and cardiomyopathy. The research explored women’s experiences of heart disease; their awareness and recognition of cardiovascular symptoms; barriers across the care pathway and assessed the burden of managing heart disease on women’s lives. The Global Heart Hub study is guided by both an independent Steering Committee and Review Committee. The committees are comprised of people with lived experience, patient organisation leaders and international clinical experts.

ACNAP 2026

IPEC2 preliminary findings were presented at the European Society of Cardiology’s ACNAP Congress 2026 on 12 June, focusing on women with elevated low-density lipoprotein cholesterol who were hospitalised at least once for a cardiac event (heart attack, stroke, or unstable angina). Uncontrolled elevated LDL cholesterol is a primary driver of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death in women across the world. The IPEC2 preliminary findings included women aged 18 years or older in the US, Canada, China and Italy.

“We now have incredible therapies to deal with high LDL-C ‘bad cholesterol’. However, the study findings highlight that women may not receive a timely diagnosis and, therefore, cannot access any treatment. The reasons are due to delays in women seeking care, frequently putting others (family) before their own health. In addition, the findings describe delays in diagnosis due to under-recognition of symptoms, life factors and clinician bias. This means that women continue to be treated later in the disease progression, sometimes at the point of their life-threatening cardiac event, which often diminishes their opportunity for better outcomes,” says Professor Vijay Kunadian, Professor of Interventional Cardiology and Cardiovascular Medicine, Newcastle University & Newcastle Hospitals, UK; and Member of IPEC2’s Steering Committee.

The preliminary findings reveal that women across every focus group experienced perceived bias in their healthcare journey, sharing their perceptions of times in their diagnosis and treatment journey where others indicated they were “too young” or “not the type” for cardiovascular disease. The gender bias in diagnosis is also evident, with women reporting that their cardiovascular disease symptoms were commonly misdiagnosed as other non-cardiac conditions, most frequently anxiety. Women described a broad and varied range of cardiovascular symptoms, including symptoms beyond those reported in guidelines. These findings highlight the need for improved symptom recognition and patient education to support earlier identification and more equitable, patient-centred care across cardiovascular settings.

“Cardiovascular disease is the leading cause of death among women, and the IPEC2 findings confirm that women continue to experience late, missed or misdiagnosed heart disease, often compounded by fragmented care. Women often experience symptoms that differ from those traditionally described in men, yet these are frequently not recognised as cardiac. We need to think ‘heart first’ for every woman, everywhere,” says Neil Johnson, Executive Director, Global Heart Hub.

IPEC2 seeks to deepen understanding of women’s experiences with cardiovascular disease by collecting robust patient experience data. The research guides recommendations towards improving patient care for women. The preliminary findings highlighted the need for improved symptom recognition and patient education to support earlier identification and more equitable, patient-centred care across cardiovascular settings.

Learn more about IPEC2: globalhearthub.org/ipec2 

Global Heart Hub’s Insights and Patient Experiences with Cardiovascular Disease (IPEC) study is a patient-led initiative made possible with the support of Amgen Inc., Daiichi Sankyo Europe, and Novartis Pharmaceuticals Corporation.

About Global Heart Hub:

Established in 2019 and headquartered in Ireland, Global Heart Hub (GHH) is the first international non-profit organisation established to provide a voice for those living with, or affected by, cardiovascular disease. We are an alliance of 150+ heart patient organisations across 40+ countries, aiming to create a unified global voice for those living with or affected by heart disease. Learn more: globalhearthub.org